Key Takeaways
-
Opus Genetics has dosed the first participant in its phase 1/2 trial of OPGx-RDH12 following FDA IND clearance in October 2026
-
The investigational AAV-based gene therapy aims to deliver a functional RDH12 gene to photoreceptors, potentially preserving retinal function and vision
-
The trial will evaluate safety, tolerability, retinal structure, and visual function in patients with RDH12-LCA
Opus Genetics has dosed the first person in its phase 1/2 clinical trial evaluating OPGx-RDH12, an investigational gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA), a rare inherited retinal disease that causes progressive vision loss beginning in early childhood.
The milestone follows FDA clearance of the company's investigational new drug (IND) application in October 2026 and marks the advancement of Opus Genetics' third gene therapy program into clinical development.
OPGx-RDH12 is an adeno-associated virus (AAV)-based gene therapy designed to deliver a functional copy of the RDH12 gene directly to retinal photoreceptor cells. The trial will assess safety and tolerability, along with exploratory measures of retinal structure and visual function.
“RDH12-LCA causes progressive vision loss beginning at a very young age, underscoring the urgency of developing treatments that may preserve retinal function before further deterioration occurs,” said George Magrath, MD, chief executive officer of Opus Genetics.
RDH12-LCA affects approximately 2,500 individuals in the United States and an estimated 30,900 worldwide, according to Opus. The disease can produce structural retinal changes by age 2, with vision loss often progressing rapidly during adolescence. No FDA-approved treatments are currently available.
Preclinical studies in cell and mouse models demonstrated restoration of RDH12 activity and functional improvements, supporting the therapy's advancement into clinical testing.
The program is being developed in collaboration with the Global RDH12 Alliance, comprising RDH12 Fund for Sight in the United States, and Eyes on the Future in the United Kingdom. Established in July 2025, the partnership includes a commitment of up to $1.6 million toward development costs, subject to specified milestones and obligations.